Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.40 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL9468373 | 1.00 | PARP1 (0.45) | PARP1HPGDMEN1KMT2ACYP1A2 | |
| Potassium Ion SCHEMBL1473627 | 1.00 | PARP1 (0.45) | PARP1HPGDMEN1KMT2ACYP1A2 | |
| SCHEMBL12750212 | 0.84 | PARP1 (0.47) | PARP1HPGDMEN1KMT2ACYP1A2 | |
| SCHEMBL9468377 | 0.83 | PARP1 (0.46) | PARP1HPGDMEN1KMT2ACYP1A2 | |
| SCHEMBL9468379 | 0.83 | PARP1 (0.46) | PARP1HPGDMEN1KMT2ACYP1A2 | |
| SCHEMBL9468372 | 0.83 | PARP1 (0.46) | PARP1HPGDMEN1KMT2ACYP1A2 | |
| Potassium Ion SCHEMBL1471686 | 0.82 | PARP1 (0.45) | PARP1HPGDMEN1KMT2AALDH1A1 | |
| Potassium Ion SCHEMBL1471160 | 0.82 | CES2 (0.47) | PARP1HPGDMEN1KMT2AALDH1A1 | |
| Potassium Ion SCHEMBL1471685 | 0.82 | PARP1 (0.45) | PARP1HPGDMEN1KMT2AALDH1A1 | |
| Potassium Ion SCHEMBL1471162 | 0.82 | CES2 (0.47) | PARP1HPGDMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915304-B2 | Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting MPT | CONGENIA S.R.L. (IT) | 2011-03-29 | — | — | US | disclosed |
| EP-2091531-B1 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | CONGENIA S R L (IT) | 2010-11-24 | — | — | EP | disclosed |
| US-20100099736-A1 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | CONGENIA S.R.L. (IT) | 2010-04-22 | — | — | US | disclosed |
| EP-2091531-A2 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | Congenia S.r.l. (IT) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008067863-A2 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | CONGENIA S.R.L. (IT) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099736-A1 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | CYC1, MTPN, TXN2 | PARP1 1845/4885HPGD 427/4885MEN1 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.